Advanced search
Publication Cover
Leukemia & Lymphoma Volume 53, 2012 - Issue 3
Submit an article Journal homepage
500
Views
20
CrossRef citations to date
0
Altmetric
Research Article

Improved outcome for very elderly patients with diff use large B-cell lymphoma in the immunochemotherapy era

Sverker HasselblomSection of Hematology and Coagulation, Department of Internal Medicine
,
Martin StensonSection of Hematology and Coagulation, Department of Internal Medicine
,
Olle WerleniusSection of Hematology and Coagulation, Department of Internal Medicine
,
Monica SenderSection of Hematology and Coagulation, Department of Internal Medicine
,
Catharina LewerinSection of Hematology and Coagulation, Department of Internal Medicine
,
Ulrika HanssonDepartment of Pathology and Cytology, Sahlgrenska University Hospital, Gothenburg, Sweden
,
Herman Nilsson-EhleSection of Hematology and Coagulation, Department of Internal Medicine
&
Per-Ola AnderssonSection of Hematology and Coagulation, Department of Internal MedicineCorrespondence[email protected]
 show all
Pages 394-399 | Received 19 May 2011, Accepted 30 Jul 2011, Published online: 10 Oct 2011

References

  • Hasselblom S, Ridell B, Nilsson-Ehle H, . The impact of gender, age and patient selection on prognosis and outcome in diffuse large B-cell lymphoma - a population-based study. Leuk Lymphoma 2007;48:736–745.
  • Krol AD, le Cessie S, Snijder S, . Non-Hodgkin's lymphoma in the Netherlands: results from a population-based registry. Leuk Lymphoma 2003;44:451–458.
  • A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Eng J Med 1993;329:987–994.
  • Kouroukis CT, Browman GP, Esmail R, . Chemotherapy for older patients with newly diagnosed, advanced-stage, aggressive-histology non-Hodgkin lymphoma: a systematic review. Ann Intern Med 2002;136:144–152.
  • Peters FP, Fickers MM, Erdkamp FL, . The effect of optimal treatment on elderly patients with aggressive non-Hodgkin's lymphoma: more patients treated with unaffected response rates. Ann Hematol 2001;80:406–410.
  • Coiffier B, Lepage E, Briere J, . CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Eng J Med 2002;346:235–242.
  • Coiffier B, Thieblemont C, Van Den Neste E, . Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 2010;116:2040–2045.
  • Bairey O, Benjamini O, Blickstein D, . Non-Hodgkin's lymphoma in patients 80 years of age or older. Ann Oncol 2006;17:928–934.
  • Thieblemont C, Grossoeuvre A, Houot R, . Non-Hodgkin's lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome. Ann Oncol 2008;19:774–779.
  • Sehn LH, Donaldson J, Chhanabhai M, . Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005;23:5027–5033.
  • Peyrade F, Jardin F, Thieblemont C, . Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol 2011;12:460–468.
  • Weidmann E, Neumann A, Fauth F, . Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas. Ann Oncol 2011;22:1839–1844.
  • Lister TA, Crowther D, Sutcliffe SB, . Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989;7:1630–1636.
  • Hryniuk WM, Goodyear M. The calculation of received dose intensity. J Clin Oncol 1990;8:1935–1937.
  • Cheson BD, Horning SJ, Coiffier B, . Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
  • Osby E, Hagberg H, Kvaloy S, . CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial. Blood 2003;101:3840–3848.
  • Janssen-Heijnen ML, van Spronsen DJ, Lemmens VE, . A population-based study of severity of comorbidity among patients with non-Hodgkin's lymphoma: prognostic impact independent of International Prognostic Index. Br J Haematol 2005;129:597–606.
  • Moller MB, Pedersen NT, Christensen BE. Diffuse large B-cell lymphoma: clinical implications of extranodal versus nodal presentation--a population-based study of 1575 cases. Br J Haematol 2004;124:151–159.
  • Steen B. The elderly yesterday, today and tomorrow: aspects on cohort differences from the gerontological and geriatric population studies in Goteborg, Sweden (H70). Arch Gerontol Geriatr Suppl 2002;8:359–370.
  • Ahlblom A, Drefahl S, Lundstrom H. [The aging population. Continuing increase of average longevity is a controversial and exciting question]. Lakartidningen 2010;107:3048–3051.
  • Italiano A, Jardin F, Peyrade F, . Adapted CHOP plus rituximab in non-Hodgkin's lymphoma in patients over 80 years old. Haematologica 2005;90:1281–1283.
  • Pfreundschuh M. How I treat elderly patients with diffuse large B-cell lymphoma. Blood 2010;116:5103–5110.
  • Hainsworth JD, Flinn IW, Spigel DR, . Brief-duration rituximab/chemotherapy followed by maintenance rituximab in patients with diffuse large B-cell lymphoma who are poor candidates for R-CHOP chemotherapy: a phase II trial of the Sarah Cannon Oncology Research Consortium. Clin Lymphoma Myeloma Leuk 2010;10:44–50.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.